Table 2. Detection of cytomegalovirus drug resistance mutations in the UL97 and UL54 genes by Sanger and next-generation sequencing.
| PATIENT | SANGER UL97 | NGS (Coverage %) UL97 | GCVa RATIO |
SANGER UL54 | NGS Coverage % UL54 | GCV/FOS/CDVa RATIO |
|---|---|---|---|---|---|---|
| 1 | L595S (15%) | 9.2 | ||||
| 2 | M460V (19%) | 8.3 | ||||
| 3 | A594V | A594V (20%) | 8.3 | |||
| 4 | M460V | M460V (29%) | 8.3 | |||
| 5 | M460V (19%) | 8.3 | ||||
| 6 | L595S (14%) | 9.2 | ||||
| 7 | L595S | L595S (20%) | 9.2 | |||
| 8 | C592G | C592G+M460V (26%/14%) | 2.9/8.3 | |||
| 9 | H520Q | H520Q (30%) | 10 | |||
| 10 | M460V | M460V (31%) | 8.3 | P522A | P522A (22%) | 3/1/4.1 |
| 11 | L595S | L595S (20%) | 9.2 | |||
| 12 | M460V | M460V (26%) | 8.3 | |||
| 13 | M460I | M460I (31%) | 5 | D413A | D413A (24%) | 6.5/0.8/11 |
| 14 | A594P | A594P (31%) | 3 | |||
| 15 | L595S | L595S (23%) | 9.2 | |||
| 16 | L595W | L595W+A594V (21%/7%) | 5.1/8.3 |
aIC50 of mutant /IC50 of wild type. If IC50 >5 the resistance was considered of high grade while an IC50 <3 was considered as low-grade resistance.
GCV: ganciclovir, FOS: foscarnet, CDV:cidofovir